Financial Review: CardioGenics (OTCMKTS:CGNH) & PROCEPT BioRobotics (NASDAQ:PRCT)

PROCEPT BioRobotics (NASDAQ:PRCT) and CardioGenics (OTCMKTS:CGNH) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

Profitability

This table compares PROCEPT BioRobotics and CardioGenics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PROCEPT BioRobotics	-31.82%	-27.70%	-20.29%
CardioGenics	N/A	N/A	N/A

Analyst Recommendations

This is a summary of current ratings and recommmendations for PROCEPT BioRobotics and CardioGenics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PROCEPT BioRobotics	2	5	7	0	2.36
CardioGenics	0	0	0	0	0.00

PROCEPT BioRobotics currently has a consensus price target of $41.36, suggesting a potential upside of 57.31%. Given PROCEPT BioRobotics’ stronger consensus rating and higher possible upside, research analysts clearly believe PROCEPT BioRobotics is more favorable than CardioGenics.

Valuation & Earnings

This table compares PROCEPT BioRobotics and CardioGenics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PROCEPT BioRobotics	$322.02 million	4.65	-$95.57 million	($1.82)	-14.45
CardioGenics	N/A	N/A	N/A	N/A	N/A

CardioGenics has lower revenue, but higher earnings than PROCEPT BioRobotics.

Institutional and Insider Ownership

89.5% of PROCEPT BioRobotics shares are owned by institutional investors. 6.6% of PROCEPT BioRobotics shares are owned by company insiders. Comparatively, 41.4% of CardioGenics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

PROCEPT BioRobotics beats CardioGenics on 5 of the 9 factors compared between the two stocks.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

About CardioGenics

CardioGenics Holdings Inc. engages in the development and commercialization of diagnostic test products for the in vitro diagnostics testing market in the United States, Canada, Europe, and internationally. Its products include QL Care Analyzer, a portable, stand-alone, and automated point-of-care (POC) immunoassay analyzer that uses a proprietary self-metering cartridge to perform immunoassay tests at the POC; a series of immunoassay tests to identify cardiac markers in the blood at the time of a heart attack; and paramagnetic beads that are used as solid surfaces in heterogeneous immunoassay tests by clinical and research laboratories. The company was formerly known as Jag Media Holdings, Inc. and changed its name to CardioGenics Holdings Inc. in 2009. The company was founded in 1997 and is headquartered in Mississauga, Canada.